Key result
Lipid-lowering therapy is advisable to achieve target lipid levels in patients with secondary hyperlipidemia associated with nephrotic syndrome, hypothyroidism, and non-alcoholic fatty liver disease.
Why the study?
Secondary hyperlipidemia contributes significantly to atherosclerosis in somatic diseases, yet its management is limited in international guidelines.
Does lipid-lowering therapy improve lipid levels in patients with secondary hyperlipidemia due to somatic diseases?
Does lipid-lowering therapy improve lipid levels in patients with secondary hyperlipidemia due to somatic diseases?
This review highlights the importance of utilizing lipid-lowering therapy to manage secondary hyperlipidemia and reduce cardiovascular risk in patients with specific somatic diseases.
Supports lipid-lowering consideration in secondary hyperlipidemia; leaves open randomized outcome trials before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Мамедов et al. (2021) conducted a review in Secondary hyperlipidemia in somatic diseases (nephrotic syndrome, hypothyroidism, non-alcoholic fatty liver disease). Lipid-lowering therapy was evaluated. Lipid-lowering therapy is advisable to achieve target lipid levels in patients with secondary hyperlipidemia associated with nephrotic syndrome, hypothyroidism, and non-alcoholic fatty liver disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: